Argenx Takes Slow But Steady Approach To Vyvgart Sales
Amid Pandemic-Related And Educational Blocks
Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.
You may also be interested in...
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.